Craig-Hallum analyst Matt Hewitt maintained a Buy rating on BioLife Solutions (BLFS – Research Report) on January 18 and set a price target of $21.00. The company’s shares opened today at $17.30.
According to TipRanks, Hewitt is an analyst with an average return of -5.8% and a 41.63% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Codexis, Apyx Medical, and Ligand Pharma.
Currently, the analyst consensus on BioLife Solutions is a Strong Buy with an average price target of $23.67, implying a 36.82% upside from current levels. In a report released on January 9, Lake Street also maintained a Buy rating on the stock with a $20.00 price target.
See the top stocks recommended by analysts >>
BLFS market cap is currently $773.5M and has a P/E ratio of -7.24.
Based on the recent corporate insider activity of 161 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLFS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions (BLFS) Company Description:
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
Read More on BLFS:
- BioLife Solutions price target raised to $20 from $15 at Lake Street
- BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue
- BioLife Solutions sees FY23 revenue $143.3M, consensus $144.37M
- BioLife Solutions sees Q4 revenue $32.7M, consensus $33.82M
- BioLife Solutions management to meet virtually with KeyBanc
